Biologic agents for IBD come of age as host–microbe interactions emerge

IF 45.9 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Nature Reviews Gastroenterology &Hepatology Pub Date : 2024-12-13 DOI:10.1038/s41575-024-01029-5

Leolin Katsidzira, Benjamin Misselwitz

引用次数: 0

Abstract

In 2024, there were major advances in inflammatory bowel disease research. Treatment strategies with biologic agents for inflammatory bowel disease matured, and gut microbiota–bacteriophage–host interaction emerged as a new frontier to target.

Abstract Image

查看原文本刊更多论文

2024 年，炎症性肠病研究取得了重大进展。使用生物制剂治疗炎症性肠病的策略日趋成熟，肠道微生物群-噬菌体-宿主相互作用成为新的靶向领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Gastroenterology &Hepatology 医学-胃肠肝病学

CiteScore

52.30

自引率

0.60%

发文量

147

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Gastroenterology & Hepatology aims to serve as the leading resource for Reviews and commentaries within the scientific and medical communities it caters to. The journal strives to maintain authority, accessibility, and clarity in its published articles, which are complemented by easily understandable figures, tables, and other display items. Dedicated to providing exceptional service to authors, referees, and readers, the editorial team works diligently to maximize the usefulness and impact of each publication. The journal encompasses a wide range of content types, including Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements, all pertinent to gastroenterologists and hepatologists. With its broad scope, Nature Reviews Gastroenterology & Hepatology ensures that its articles reach a diverse audience, aiming for the widest possible dissemination of valuable information. Nature Reviews Gastroenterology & Hepatology is part of the Nature Reviews portfolio of journals.